Category: Drug Safety Alerts
-
Picato Skin Cancer Risk Investigation By European Drug Regulator Prompts Sales Suspension In Europe
January 2020 News Report: FDA “is gathering data and information to investigate the safety concern related to Picato” (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: The UK’s Medicines and Health products Regulatory…
-
Acute Renal Failure With Uloric Reported Almost 6 Times More Frequently Compared To Some Other Gout Drugs
Uloric-Related Acute Kidney Injury: Researchers Find A Significantly Higher Reporting Odds Ratio In Women Compared To Men (Posted by Tom Lamb at DrugInjuryWatch.com) Uloric (febuxostat) is a popular urate-lowering therapy (ULT) used…
-
Gilenya Birth Defects Warnings Issued By Drug Safety Regulators In Canada And Europe — But Not By FDA In The US
Gilenya Increased Risk of Major Congenital Malformations Such As Renal / Kidney And Musculoskeletal Abnormalities, Atrial Septal Defects (Posted by Tom Lamb at DrugInjuryWatch.com) On December 19, 2019 Health Canada issued a…
-
Hemophilia Drug Hemlibra: Adverse Events Reports And Patient Deaths Raise Some Concerns
November 2019 NEJM Letter Points Out Possible Public Health Issue For Hemlibra Used By Hemophilia A Patients (Posted by Tom Lamb at DrugInjuryWatch.com) We recently learned about drug safety issues involving Hemlibra…
-
Zantac FDA Warning In September 2019 Leads To Lawsuits For Patients Diagnosed With Cancer
Cases Involve Stomach, Colon, Rectal, Bladder, Kidney, And Pancreatic Cancers Diagnosed After Taking Zantac (Posted by Tom Lamb at DrugInjuryWatch.com) Zantac cancer lawsuits are being filed for patients diagnosed with certain types…
-
Lemtrada Use Restrictions Issued By EMA’s Pharmacovigilance Risk Assessment Committee Due To Safety Issues
Action Due To Reports Of Lemtrada Side Effects Including Deaths Related To Immune Complications And Heart Or Circulatory Disorders (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2019 the Pharmacovigilance Risk…
-
Uloric Side Effects Lead To An Increased Risk of Patient Cardiovascular Deaths, Says Health Canada
Drug Safety Warning: Watch For Myocardial Infarction, Stroke, And Cardiac Failure In People Who Are Taking Uloric (Posted by Tom Lamb at DrugInjuryWatch.com) In early November 2019 Health Canada warned that in…
-
European Medicines Agency (EMA) Warns Xeljanz Increases Risk Of Pulmonary Embolism (PE) And Deep Vein Thrombosis (DVT)
Recommends That Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots As Well Aa In Patients Older Than 65 Years Of Age (Posted by Tom Lamb at DrugInjuryWatch.com)…
-
Lemtrada Adverse Events May Occur More Frequently Than Previously Noted By Drug Safety Regulators And Researchers
Ten Deaths Identified As Being Most Probably Related To Lemtrada, With Six Of These Cases Not Previously Reported, According To New Study (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "Dear Healthcare Professional…